Verapamil in the Treatment of Hypertrophic Cardiomyopathy
Authors: DOUGLAS R. ROSING
Journal: Annals of Internal Medicine (1982)

Editorials1 May 1982Verapamil in the Treatment of Hypertrophic CardiomyopathyDOUGLAS R. ROSING, M.D., STEPHEN E. EPSTEIN, M.D.DOUGLAS R. ROSING, M.D.Search for more papers by this author, STEPHEN E. EPSTEIN, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-96-5-670 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptFor many years beta-adrenergic receptor blocking agents have been the primary pharmacologic agents for treating patients with hypertrophic cardiomyopathy (1, 2). The beneficial hemodynamic and symptomatic effects produced by these drugs are derived from their inhibition of sympathetic stimulation to the heart (3). Until recently, if beta blocker therapy failed to provide a satisfactory therapeutic response in patients with left ventricular outflow tract obstruction, an operation was done to control symptoms, usually a ventricular septal myotomy-myectomy.Several studies, however, have shown that administering verapamil, the prototype calcium-channel blocking agent, to patients with hypertrophic cardiomyopathy can reduce left ventricular outflow tract...References1. COHENBRAUNWALD LE. Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation. 1967;35:847-51. CrossrefMedlineGoogle Scholar2. SWANBELLOAKLEYGOODWIN DBCJ. Analysis of symptomatic course and prognosis and treatment of hypertrophic obstructive cardiomyopathy. Br Heart J. 1971;33:671-85. CrossrefMedlineGoogle Scholar3. HARRISONBRAUWALDGLICKMASONCHIDSEYROSS DEGDCJ. Effects of beta adrenergic blockade on the circulation with particular reference to observations in patients with hypertrophic subaortic stenosis. Circulation. 1964;29:84-98. CrossrefMedlineGoogle Scholar4. ROSINGKENTBORERSEIDESMARONEPSTEIN DKJSBS. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: I. Hemodynamic effects. Circulation. 1979;60:1201-7. CrossrefMedlineGoogle Scholar5. KALTENBACHHOPFKOBERBUSSMANKELLERPETERSEN MRGWMY. Treatment of hypertrophic obstructive cardiomyopathy with verapamil. Br Heart J. 1979;42:35-42. CrossrefMedlineGoogle Scholar6. ROSINGKENTMARONEPSTEIN DKBS. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: II. Effects on exercise capacity and symptomatic status. Circulation. 1979;60:1208-13. CrossrefMedlineGoogle Scholar7. ROSINGCONDITMARON DJB. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. III. Effects of long-term administration. Am J Cardiol. 1981;48:545-53. CrossrefMedlineGoogle Scholar8. HASINLEWISLEWISWEISSGOTSMAN YBNAM. Long term effect of verapamil in hypertrophic cardiomyopathy. Int J Cardiol. In press. Google Scholar9. EPSTEINROSING SD. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation. 1981;64:437-41. CrossrefMedlineGoogle Scholar10. KLEINLANGDI SEONIKAPLINSKY HREE. Verapamil-digoxin interaction. N Engl J Med. 1980;303:160. Letter. CrossrefMedlineGoogle Scholar11. BONOWROSINGBACHARACH RDS. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation. 1981;64:787-96. CrossrefMedlineGoogle Scholar12. HANRATHMATHEYKREMERSONNTAGBLEIFELD PDPFW. Effect of verapamil on left ventricular isovolumic relaxation time and regional left ventricular filling in hypertrophic cardiomyopathy. Am J Cardiol. 1980;45:1258-64. CrossrefMedlineGoogle Scholar13. BONOWOSTROWROSING RHD. Verapamil-induced changes in ventricular volume and diastolic function in hypertrophic cardiomyopathy: mechanisms for reduced subvalvular gradient and improved symptoms. Circulation. 1981;64 (suppl IV): IV-11. Abstract. Google Scholar14. HENRYCLARKGRIFFITHEPSTEIN WCJS. Mechanism of left ventricular outflow obstruction in patients with obstructive asymmetric septal hypertrophy (idiopathic hypertrophic subaortic stenosis). Am J Cardiol. 1975;35:337-45. CrossrefMedlineGoogle Scholar15. KOLHARDTBAUERKRAUSEFLECKENSTEIN MBHA. New selective inhibitors of the transmembrance Ca conductivity in mammalian myocardial fibers: studies with voltage clamp technique. Experientia. 1972;28:288-9. CrossrefMedlineGoogle Scholar16. CRANEFIELDARONSONWIT PRA. Effect of verapamil on the normal action potential and on a calcium-dependent slow response of canine cardiac Purkinje fibers. Circ Res. 1974;34:204-13. CrossrefMedlineGoogle Scholar17. LORELLPAULUSGROSSMANWYNNECOHN BWWJP. Modification of abnormal left ventricular diasytolic properties by nifedipine in patients with hypertrophic cardiomyopathy. Circulation. 1982;65:499-507. CrossrefMedlineGoogle Scholar18. KOIDEKAKIHANATAKABATAKE TMY. Long-term clinical effect of calcium inhibitors in hypertrophic cardiomyopathy compared to the effect of beta-blocking agents: a preliminary report with special reference to the beneficial effect of nifedipine on angina pectoris. Jap Heart J. 1981;22:87-102. CrossrefMedlineGoogle Scholar19. ZELISFLAIM RS. "Calcium influx blockers" and vascular smooth muscle: do we really understand the mechanism? Ann Intern Med. 1981;94:124-6. LinkGoogle Scholar20. TROESCHHIRZELJENNIKRAYENBUHL MHRH. Reduction of septal thickness following verapamil in patients with asymmetric septal hypertrophy. Circulation. 1979;60 (suppl II):II-155. Abstract. Google Scholar21. MARONEPSTEIN BS. The problem of assessing prognosis in hypertrophic cardiomyopathy. J Cardiovasc Med. 1980;5:1009-14. Google Scholar22. MARONSAVAGEWOLFSONEPSTEIN BDJS. Prognostic significance of 24 hour ambulatory electrocardiography monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol. 1981;48:252-7. CrossrefMedlineGoogle Scholar23. MARONMERRILLFREIERKENTEPSTEINMORROW BWPKSA. Long-term clinical course and symptomatic status of patients after operation for hypertrophic subaortic stenosis. Circulation. 1978;57:1205-13. CrossrefMedlineGoogle Scholar24. MARONLIPSONROBERTSSAVAGEEPSTEIN BLWDS. "Malignant" hypertrophic cardiomyopathy: identification of a subgroup of families with unusually frequent premature deaths. Am J Cardiol. 1978:41:1133-40. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Cardiology Branch National Heart, Lung, and Blood Institutes National Institutes of Health Bethesda, Maryland PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByValvular Heart DiseaseSyncope induced by propranolol in hypertrophic cardiomyopathyPharmakologie und antihypertensive Wirksamkeit der KalziumantagonistenIndications for Calcium AntagonistsThe Role of Calcium Antagonists in Acute Myocardial InfarctionIndikationen für Calcium-AntagonistenUse of calcium channel blockers in hypertrophic cardiomyopathyWirkung von Nifedipin bei hypertrophisch obstruktiver KardiomyopathiePeripartum cardiomyopathyHypertrophic Cardiomyopathy and the AthleteObstructive hypertrophic cardiomyopathy with left-sided cardiac failure: Improvement after verapamil treatmentVerapamil: Full spectrum calcium channel blocking agent: An overviewPossible treatment of pre-eclampsia with calcium channel blocking agentsThe calcium channel blockers: Pharmacology and clinical applicationsCalcium antagonists: A new class of drugs 1 May 1982Volume 96, Issue 5Page: 670-672KeywordsCardiomyopathiesDrugsHeartHemodynamicsLeft ventricular outflow tract Issue Published: 1 May 1982 PDF DownloadLoading ...